CN1046412C - 骨髓净化剂及制备方法 - Google Patents

骨髓净化剂及制备方法 Download PDF

Info

Publication number
CN1046412C
CN1046412C CN92103061A CN92103061A CN1046412C CN 1046412 C CN1046412 C CN 1046412C CN 92103061 A CN92103061 A CN 92103061A CN 92103061 A CN92103061 A CN 92103061A CN 1046412 C CN1046412 C CN 1046412C
Authority
CN
China
Prior art keywords
bone marrow
dbp
marrow
vial
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92103061A
Other languages
English (en)
Other versions
CN1065994A (zh
Inventor
吴祖泽
曹菊荣
裴雪涛
王绪明
薛惠华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute Of Radiology Academy Of Military Medical Sciences
Institute of Radiation Medicine of CAMMS
Original Assignee
Institute Of Radiology Academy Of Military Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Radiology Academy Of Military Medical Sciences filed Critical Institute Of Radiology Academy Of Military Medical Sciences
Priority to CN92103061A priority Critical patent/CN1046412C/zh
Publication of CN1065994A publication Critical patent/CN1065994A/zh
Application granted granted Critical
Publication of CN1046412C publication Critical patent/CN1046412C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明是将邻苯二甲酸正丁酯(DBP)用于体外骨髓净化,其特点是可以选择性杀伤存在于骨髓中的少量残留白血病细胞或肿瘤细胞,但不伤害原有的正常骨髓造血功能。应用DBP为骨髓净化剂,结合骨髓体外液体培养可以清除存在于骨髓中的残留肿瘤细胞,从而为净化自体骨髓移植治疗白血病与肿瘤构建了一个安全、有效的配套净化方法。

Description

骨髓净化剂及制备方法
本发明涉及一种用于体外净化骨髓中残留白血病细胞的净化剂及制备方法。
骨髓移植是目前公认的治疗白血病的一个有效措施。在缺少近亲供髓的情况下,利用病人自身在缓介期的骨髓移植是另一个可行的治疗途径。由于缓介期白血病人骨髓中存在少量残留的白血病细胞,因而移植后原病复发率高。近年来,许多学者致力于寻找一个能够在体外净化骨髓中残留白血病细胞的净化剂。采集的骨髓在体外经过这种净化剂处理后,能够有效地清除其中的残留白血病细胞,但不伤害正常的骨髓造血功能。因而,经过净化后的自体骨髓移植可以有效地保证病人在经大剂量化疗与放疗后的造血恢复,巩固白血病人长期处于完全缓解状态,从而达到对白血病的根治目的。
反映该技术的文件:已经发表的可以用作骨髓净化的化合物,如:4-hydroxyperoxycyclophosphamide(4HC)和mafosfamide(Asta-Z 7557)等,它们都是一类细胞毒剂,不仅可以杀伤白血病细胞,同时对人类的正常造血细胞有强烈的毒性作用,且敏感性随个体而异。在当前尚无简易的人类造血干细胞检测方法的情况下,不易掌握这类净化剂的最适净化剂量,因而容易导致移植的失败。
1.N.C.Gorin et al:Autologous bone marrow transplantation using
marrow incubated with Asta Z-7557 in adult acute leukemia.Blood
Vol.67,No.5,1986:pp1367-1376
2.H.sindermann et al:Bone marrow purging with mafosfamide-
A critical survey.Blut Vol.59,1989:pp432-441
本发明的目的在于克服现有净化剂的缺点而提出的一种在化学功能与结构上各具特色的新型骨髓净化剂。
本发明是在白血病人骨髓的体外长期液体培养中加入邻苯二甲酸正丁酯(Dibutyl phthalate,DBP)和人血清白蛋白或吐温-80配制而成的制剂,可以显著加速白血病细胞的死亡,同时又能较好的保留正常造血细胞的功能,从而明著加速白血病细胞的死亡,同时又能较好的保留正常造血细胞的功能,从而明显提高了对体外骨髓的净化效果。
该净化剂的制备方法:A:DBP,分析纯,分子量278.34,经气相色谱分析含量须在99.5-99.9%。在一
只玻璃瓶中装入200mg DBP高压灭菌(简称A瓶)。在另一只玻璃瓶中装入10ml
5%人血清白蛋白溶液(简称B瓶)。临用前,从B瓶中抽取全量人血清白蛋白溶
液注入A瓶,用手剧烈振摇,制成均匀乳剂。在待净化的骨髓细胞悬液中按100-
200μg/2×106骨髓有核细胞/ml的比例加入由上述方法制备的DBP乳剂。B:DBP,分析纯,分子量278.34,经气相色谱分析含量须在99.5-99.9%。在
一只玻璃瓶中装入200mg DBP和80mg吐温-80,高压灭菌。用前,注入
10ml生理盐水,剧烈振摇,制成均匀乳剂,在待净化的骨髓细胞悬液中按100-
200μg/2×106骨髓有核细胞/ml的比例,加入由上述方法制备的DBP乳剂。
本发明的骨髓净化方法与以往多种方法比较,有以下优点:1.DBP对白血病与肿瘤细胞有选择性杀伤与清除的作用;2.白血病人在发作期可作原代肿瘤细胞对DBP的敏感性试验;3.净化所需时间(4-9天)与临床骨髓移植前予处理时间基本一致,因而,采集的骨髓细胞不需作冷冻保存处理。4.净化后骨髓细胞数量与功能可以满足临床移植的需要,回输骨髓不再含DBP,因而骨髓净化处理对人体无毒副作用,病人移植后造血恢复顺利。
实施例一:
为了证明DBP净化骨髓的效果。我们从一例急性粒细胞性白血病患者(AML,M2a)采集骨髓。在体外琼脂培养条件下,由5%人血清白蛋白配制的DBP乳剂可以明显抑制白血病细胞(AML-CFU)的生长,其抑制程度随DBP浓度的增加而增强。与正常人骨髓造血细胞(CFU-GM)相比,DBP对原代白血病细胞有高度的选择性抑制效果(图1)。
实施例二:
在体外液体培养中,由5%人血清白蛋白配制的DBP乳剂有明显的加速骨髓中白血病细胞(AML-CFU)破坏作用
在体外液体培养中,由5%人血清白蛋白配制的DBP乳剂有明显的加速骨髓中白血病细胞(AML-CFU)破坏作用。培养9天后,对照的培养瓶中(不加入DBP),白血病细胞比培养前虽有减少,但仍有15%未被清除;然而,在含有DBP的培养瓶中,白血病细胞已降至不可检出的程度。随着白血病细胞的清除,原来处于生长抑制状态的正常造血功能趋于恢复。因此,DBP不仅可以加速对白血病细胞的清除,而且可以加快正常造血功能的恢复(图2)。上述研究结果证实了DBP具有净化白血病细胞、保护正常造血的功能。

Claims (1)

1.一种在净化体外骨髓中残留白血病细胞及其它侵犯骨髓的恶性肿瘤细胞的净化剂的制备方法,其特征在于:
A:邻苯二甲酸正丁酯,分子量278.34,经气相色谱分析含量须在99.5-99.9%;在A玻璃瓶中装入200毫克邻苯二甲酸正丁酯,高压灭菌,在B玻璃瓶中装入10毫升5%人血清白蛋白溶液;临用前,从B瓶中抽取全量人血清白蛋白溶液注入A瓶,用手剧烈振摇,制成均匀乳剂;
B:邻苯二甲酸正丁酯、分子量278.34,经气相色谱分析含量须在99.5-99.9%;在一只玻璃瓶中装入200毫克邻苯二甲酸正丁酯和80毫克吐温-80,高压灭菌;用前,注入10毫升生理盐水。剧烈振摇,制成均匀乳剂。
CN92103061A 1992-04-29 1992-04-29 骨髓净化剂及制备方法 Expired - Fee Related CN1046412C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN92103061A CN1046412C (zh) 1992-04-29 1992-04-29 骨髓净化剂及制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN92103061A CN1046412C (zh) 1992-04-29 1992-04-29 骨髓净化剂及制备方法

Publications (2)

Publication Number Publication Date
CN1065994A CN1065994A (zh) 1992-11-11
CN1046412C true CN1046412C (zh) 1999-11-17

Family

ID=4940006

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92103061A Expired - Fee Related CN1046412C (zh) 1992-04-29 1992-04-29 骨髓净化剂及制备方法

Country Status (1)

Country Link
CN (1) CN1046412C (zh)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARCAINOGENESIS (UNITED KINGDOM) 1990.1.1 YAMAMOTO S.等,ANTI-TUMOR PROMOTING ACTION OF PHTHALIC ACID MONO-N-BUTYL ED TER CUPRIC SALT A BIOMI MET *

Also Published As

Publication number Publication date
CN1065994A (zh) 1992-11-11

Similar Documents

Publication Publication Date Title
TW580392B (en) Process for preparing synthetic soil-extract materials and medicaments based thereon
McElwain et al. Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan
Gorin et al. Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia
CA2137271C (fr) Dispositif permettant l'obtention d'un surnageant de thrombocytes actives, procede mettant en oeuvre le dispositif et surnageant obtenu
Epstein et al. Pseudomonas septicemia in neutropenic dogs I. Treatment with granulocyte transfusions
CA2231916A1 (en) Erythrocytes loaded with s-nitrosothiol and uses therefor
Mills et al. Bone-marrow transplant in an identical twin
CN1046412C (zh) 骨髓净化剂及制备方法
NO173655B (no) Fremgangsmaate for ekstrahering av et tetrapeptid fra biologisk materiale
JPH06511013A (ja) 血液、組織および生物流体のアルブミンーヨウ素保存
CN1249952A (zh) 血浆病毒灭活的方法及其装置
AU648823B2 (en) Antimicrobial preservation of plasma
Shohet Morphologic evidence for the in vivo activity of transfused chronic myelogenous leukemia cells in a case of massive staphylococcal septicemia
Netzel et al. TRANSPLANTATION OF SYNGENEIC BONE MARROW INCUBATED WITH LEUKOCYTE ANTIBODIES: II. CYTOTOXIC ACTIVITY OF ANTI-cALL GLOBULIN ON LEUKEMIC CELLS AND NORMAL HEMOPOIETIC PRECURSOR CELLS IN MAN
Keller et al. Studies on the factors concerned in the disappearance of bacteriophage particles from the animal body
Benestad et al. Properties of hematopoietic progenitor cells
Lundgren Induction and suppression of the cytotoxic activity of human lymphocytes in vitro by heterologous anti-lymphocyte serum
Room et al. The Inhzbitory Effect of D-Penicillamine on Human Lymphocyte Cultures Stimulated by Phytohaemagglutinin, The Antagonistic Action of L-Cysteine and Synergistic Inhibition by Copper Sulphate
US6303154B1 (en) Chemical alteration of mammal urine and mammal blood
JPH06510067A (ja) 血液、組織および生物流体のデンプン−ヨウ素保存
WO2000043403A1 (fr) Sels d'acide 2-methyl-3-butenyl-1-pyrophosphoriques et agents de traitement des lymphocytes
JPS5899419A (ja) 免疫抑制剤
Dakin Biochemistry and war problems
Haksar et al. Chlorpromazine: Inhibition of ACTH and cyclic 3′, 5′-AMP stimulated corticosterone synthesis
SU1457930A1 (ru) Способ лечени анаэробной газовой инфекции

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee